The US District Court jury in Marshall, Texas has found that the company’s Taxus Express and Taxus Liberte drug-eluting stent products infringe Saffran’s patent and that the patent is valid.
The company believes the jury verdict is unsupported by both the evidence and the law. On these grounds, the company plans to seek to overturn the verdict in post-trial motions before the District Court and, if unsuccessful, to appeal to the US Court of Appeals for the Federal Circuit. The company believes it will prevail on appeal.